Ladarixin is a dual, non-competitive allosteric inhibitor of CXCR1 and CXCR2 interleukin8 (IL-8a and IL-8b, respectively). The efficacy of CXCR1/2 inhibition prevents inflammation and autoimmune-mediated islet damage.
AZ-DF 265 is a hypoglycaemic drug which stimulates insulin release. AZ-DF-265 inhibits ATP-sensitive potassium channels and displaces [3H]-glibenclamide from the sulphonylurea receptor.